Exploring the History & Treatment of PTSD: An Interview with Dr. Paula P. Schnurr
As we celebrate Veterans Day (and Remembrance Day in Canada) and honoring military veterans, many of us think back to World War I but also many other wars throughout history. I recalled the 1980s, when Iran was engaged in an almost decade-long war with Iraq, and millions were killed or injured on both sides. In the West, the older generations may recall World War II and the Vietnam War, while the younger ones remember the more recent wars in Iraq and Afghanistan. We think of the millions who have fought, who have come back with injuries, and those who died serving their countries. But the numbers we rarely think about: How many live with Post Traumatic Stress Disorder (PTSD), a disorder often associated with but far from limited to those who served in or experienced wars. What is PTSD? The official definition for PTSD, as noted in DSM-5, requires “exposure to actual or threatened death, serious injury, or sexual violence” directly or vicariously; presence of intrusive symptoms such as memories or dreams; avoidance of trauma-related stimuli; and the presence of negative changes in mood (e.g. inability to feel happiness) and cognition (e.g. distorted view of the causes and effects of the trauma) (DSM-5; APA 2013). PTSD did not officially exist before 1980. Historically, most doctors (except military psychiatrists) assumed that exposure to horrific events in war could result only in temporary stress reactions, but this view changed following Vietnam, when some...
CONCLUSION: Prevalence of antibiotic use was high not only versus other hospitals in the region but globally including Africa, coupled with significant evidence of sub-optimal prescribing. Swift action is needed to improve future prescribing to reduce AMR. One or two areas should initially be targeted for quality improvement including development of local guidelines, documentation of antibiotic indications and/or stop/review dates. PMID: 33034234 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: Meta GeneAuthor(s): Mansour Zamanpoor, Hamid Ghaedi, Mir Davood Omrani
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
CONCLUSIONS: Considering the low number of university students disclosing sexual assaults to health professionals or support services, the results of this survey suggest more work is needed to facilitate greater disclosures to health professionals enabling victims to access the services they need regardless of alcohol use. PMID: 33032303 [PubMed - in process]
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Publication date: December 2020Source: Journal of Functional Foods, Volume 75Author(s): Tingting Wang, Lin Zheng, Tiantian Zhao, Qi Zhang, Zhitong Liu, Xiaoling Liu, Mouming Zhao
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Mario Gennaro Mazza, Rebecca De Lorenzo, Caterina Conte, Sara Poletti, Benedetta Vai, Irene Bollettini, Elisa Maria Teresa Melloni, Roberto Furlan, Fabio Ciceri, Patrizia Rovere-Querini, COVID-19 BioB Outpatient Clinic Study group, Francesco Benedetti
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Xiaoqin Liu, Trine Munk-Olsen, Clara Albiñana, Bjarni J. Vilhjálmsson, Emil M. Pedersen, Vivi Schlünssen, Marie Bækvad-Hansen, Jonas Bybjerg-Grauholm, Merete Nordentoft, Anders D. Børglum, Thomas Werge, David M. Hougaard, Preben B. Mortensen, Esben Agerbo
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): E.K. Grantham, A.S. Warden, G.S. McCarthy, A. DaCosta, S. Mason, Y. Blednov, R.D. Mayfield, R.A. Harris
More News: Accidents | Afghanistan Health | Alcoholism | Anorexia | Arthritis | Beta-Blockers | Canada Health | Cardiology | Cardiovascular | Depression | Diabetes | Eating Disorders & Weight Management | Effexor | Endocrinology | Fluoxetine | Health Management | Heart | Iran Health | Iraq Health | Men | Middle East Health | Paroxetine | Paxil | Post Traumatic Stress Disorder | Prozac | Psychiatry | Psychology | Rheumatology | Science | Sertraline | Sexual Abuse | Smokers | Statistics | Study | Vietnam Health | Websites | Zoloft